Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

1. Diagnosis and management of heparin?induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group

Diagnosis and management of heparin?induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range (...) to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New Zealand HIT Writing Group Joanne Joseph, David Rabbolini, Anoop K Enjeti, Emmanuel Favaloro, Marie‐Christine Kopp

2019 MJA Clinical Guidelines

2. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. (PubMed)

Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. This an update of the review first published in 2009.Major abdominal and pelvic surgery carries a high risk of venous thromboembolism (VTE). The efficacy of thromboprophylaxis with low molecular weight heparin (LMWH) administered during the in-hospital period is well-documented, but the optimal duration of prophylaxis after surgery remains controversial. Some studies suggest that patients undergoing

2019 Cochrane

3. Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. (PubMed)

Continuous Anticoagulation and Cold Snare Polypectomy Versus Heparin Bridging and Hot Snare Polypectomy in Patients on Anticoagulants With Subcentimeter Polyps: A Randomized Controlled Trial. Management of anticoagulants for patients undergoing polypectomy is still controversial. Cold snare polypectomy (CSP) is reported to cause less bleeding than hot snare polypectomy (HSP).To compare outcomes between continuous administration of anticoagulants (CA) with CSP (CA+CSP) and periprocedural heparin

2019 Annals of Internal Medicine Controlled trial quality: predicted high

4. Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. (PubMed)

Prolonged thromboprophylaxis with low molecular weight heparin for abdominal or pelvic surgery. This an update of the review first published in 2009.Major abdominal and pelvic surgery carries a high risk of venous thromboembolism (VTE). The efficacy of thromboprophylaxis with low molecular weight heparin (LMWH) administered during the in-hospital period is well-documented, but the optimal duration of prophylaxis after surgery remains controversial. Some studies suggest that patients undergoing

2019 Cochrane

5. Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot

Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot Heparin versus saline and occlusion in adults: A Snapshot 1 Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot Citation Corey Joseph & Angela Melder. August 2018. Occlusion between heparin saline and 0.9% sodium chloride in adults: A Snapshot. Centre for Clinical Effectiveness, Monash Health, Melbourne, Australia. Executive Summary Background The Centre for Clinical Effectiveness have (...) patency between heparinised saline and 0.9% Sodium Chloride solution in Adults. Specifically, the review will focus on central lines only. Findings ? Given the very low-quality of the evidence, it is uncertain whether heparin saline results in fewer occlusions than normal saline. 3,4 ? Low quality evidence suggests there is no difference in occlusion of line access, lumen and patient between heparin saline and normal saline. 4 ? In the short term ( 30 days) there was not difference in occlusion

2019 Monash Health Evidence Reviews

6. An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart

An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Discover Portal Discover Portal An anticoagulant, bivalirudin, may not be safer than the alternative, heparin, when unblocking arteries in the heart Published on 14 June 2016 doi: Bivalirudin is currently recommended as an alternative option to heparin to prevent (...) clotting during percutaneous coronary intervention. This is a common procedure to unblock the heart’s arteries. It is more costly but may have advantages relative to heparin, such as a more rapid action and less risk of lowering the platelet count. This review found that bivalirudin reduced risk of major bleeding compared with heparin. However, this was only when heparin was combined with a higher dose of another anti-clotting drug, a glycoprotein platelet IIb/IIIa inhibitor. When there was equivalent

2019 NIHR Dissemination Centre

7. Low molecular weight heparin (LMWH) monotherapy for recurrent abortion (RCA) with antiphospholipid system (APS): a protocol of a systematic review

Low molecular weight heparin (LMWH) monotherapy for recurrent abortion (RCA) with antiphospholipid system (APS): a protocol of a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

8. Heparin as a therapy for intrauterine fetal growth restriction: systematic review and meta-analysis

Heparin as a therapy for intrauterine fetal growth restriction: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2019 PROSPERO

9. Bivalirudin vs heparin in trans-radial coronary interventions: a meta-analysis of randomized controlled trials

Bivalirudin vs heparin in trans-radial coronary interventions: a meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2019 PROSPERO

10. Bivalirudin versus heparin in the elderly patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials

Bivalirudin versus heparin in the elderly patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g

2019 PROSPERO

11. Low dose low-molecular-weight heparin (LMWH) for thrombosis prophylaxis: systematic review with meta-analysis and trial sequential analysis

Low dose low-molecular-weight heparin (LMWH) for thrombosis prophylaxis: systematic review with meta-analysis and trial sequential analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

12. The comparative efficacy and safety of novel oral anticoagulants, warfarin and low molecular weight heparin in patients with cancer to prevent venous thromboembolism: a network meta-analysis

The comparative efficacy and safety of novel oral anticoagulants, warfarin and low molecular weight heparin in patients with cancer to prevent venous thromboembolism: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

13. The efficacy and safety of oral anticoagulants compared to low molecular weight heparin for the treatment of venous thromboembolism (VTE) in hematologic malignancies: a systematic review and meta-analysis

The efficacy and safety of oral anticoagulants compared to low molecular weight heparin for the treatment of venous thromboembolism (VTE) in hematologic malignancies: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

14. Bivalirudin versus heparin in transradial coronary interventions: a pairwise and network meta-analysis of randomized clinical trials

Bivalirudin versus heparin in transradial coronary interventions: a pairwise and network meta-analysis of randomized clinical trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

15. Direct oral anticoagulant compared to low molecular weight heparin in the treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis of randomized controlled trials

Direct oral anticoagulant compared to low molecular weight heparin in the treatment of venous thromboembolism in patients with cancer: a systematic review and meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

16. Efficacy of low molecular weight heparin (LMWH) for chronic obstructive pulmonary disease (COPD) and respiratory failure (RF): a systematic review protocol of randomized controlled trials

Efficacy of low molecular weight heparin (LMWH) for chronic obstructive pulmonary disease (COPD) and respiratory failure (RF): a systematic review protocol of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

17. What is the clinical and cost effectiveness of fondaparinux, with or without intra-procedural intravenous heparin compared to LMWH/UFH in the management of patients with UA or NSTEMI undergoing coronary angiography?

What is the clinical and cost effectiveness of fondaparinux, with or without intra-procedural intravenous heparin compared to LMWH/UFH in the management of patients with UA or NSTEMI undergoing coronary angiography? Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete

2019 PROSPERO

18. Pooled database of individual participant data from randomized trials of bivalirudin versus heparin in percutaneous coronary intervention

Pooled database of individual participant data from randomized trials of bivalirudin versus heparin in percutaneous coronary intervention Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

19. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis

Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

20. Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned GPI during primary percutaneous coronary intervention in acute myocardial infarction - a VALIDATE-SWEDEHEART substudy (PubMed)

Relationship between degree of heparin anticoagulation and clinical outcome in patients receiving potent P2Y12-inhibitors with no planned GPI during primary percutaneous coronary intervention in acute myocardial infarction - a VALIDATE-SWEDEHEART substudy Heparin is the preferred choice of anticoagulant in percutaneous coronary intervention (PCI) for acute myocardial infarction (MI). An established dosage of heparin has not yet been determined, but treatment may be optimized through monitoring (...) of activating clotting time (ACT). The aim of this study was to determine the relationship between heparin dose or ACT with a composite outcome of death, MI or bleeding using data from the registry-based, randomized, controlled and open-label VALIDATE-SWEDEHEART-trial, although patients were not randomized to heparin dose in this sub-study.Patients with MI undergoing PCI and receiving treatment with a potent P2Y12-inhibitor and anticoagulation with heparin, without the planned use of glycoprotein IIb/IIIa

2019 European heart journal. Cardiovascular pharmacotherapy Controlled trial quality: uncertain